{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T02:00:41Z","timestamp":1776218441808,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thebonejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.bone.2013.11.002","type":"journal-article","created":{"date-parts":[[2013,11,11]],"date-time":"2013-11-11T21:33:19Z","timestamp":1384205599000},"page":"105-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective"],"prefix":"10.1016","volume":"59","author":[{"given":"A.","family":"Parthan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Agodoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-7355","authenticated-orcid":false,"given":"E.","family":"Orwoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2013.11.002_bb0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17453670710015094","article-title":"Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden","volume":"79","author":"Strom","year":"2008","journal-title":"Acta Orthop"},{"key":"10.1016\/j.bone.2013.11.002_bb0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00296-008-0689-2","article-title":"Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study","volume":"29","author":"Ringe","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0015","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","article-title":"Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-011-0060-1","article-title":"Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"6","author":"Strom","year":"2011","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.bone.2013.11.002_bb0025","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0030","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"NEJM"},{"key":"10.1016\/j.bone.2013.11.002_bb0035","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"NEJM"},{"key":"10.1016\/j.bone.2013.11.002_bb0040","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2013.11.002_bb0045","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","article-title":"Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis","volume":"22","author":"Jonsson","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jval.2012.03.215","article-title":"Cost-effectiveness of denosumab versus oral bisphosphonates in the United States for post-menopausal osteoporosis (PMO)","volume":"15","author":"Parthan","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.bone.2013.11.002_bb0055","unstructured":"ADAMO trial data. Data on file \u2014 Amgen."},{"key":"10.1016\/j.bone.2013.11.002_bb0060","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.bone.2009.12.034","article-title":"Efficacy and safety of monthly ibandronate in men with low bone density","volume":"46","author":"Orwoll","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.11.002_bb0065","first-page":"S260","article-title":"Efficacy and safety of strontium ranelate in the treatment of male osteoporosis","volume":"23","author":"Kaufman","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0075","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2169\/internalmedicine.47.0591","article-title":"Efficacy of risedronate in Japanese male patients with primary osteoporosis","volume":"47","author":"Majima","year":"2008","journal-title":"Intern Med"},{"key":"10.1016\/j.bone.2013.11.002_bb0080","series-title":"Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis","article-title":"Committee for medicinal products for human use","author":"EMEA","year":"2006"},{"key":"10.1016\/j.bone.2013.11.002_bb0085","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"NEJM"},{"key":"10.1016\/j.bone.2013.11.002_bb0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00198-011-1549-6","article-title":"Adherence to treatment of primary osteoporosis and its association to fractures \u2014 the Swedish Adherence Register Analysis (SARA)","volume":"23","author":"Landfeldt","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5414\/CP201632","article-title":"Persistence and compliance of medications used in the treatment of osteoporosis \u2014 analysis using a large scale, representative, longitudinal German database","volume":"50","author":"Ziller","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.bone.2013.11.002_bb0105","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00223-012-9574-9","article-title":"Impact of a phone follow-up program on persistence with teriparatide or PTH(1\u201384) treatment","volume":"90","author":"Tamone","year":"2012","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s001980170112","article-title":"The burden of osteoporotic fractures: a method for setting intervention thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00198-002-1316-9","article-title":"Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study","volume":"14","author":"Hasserius","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","article-title":"Mortality after osteoporotic fractures","volume":"15","author":"Johnell","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","article-title":"Excess mortality after hospitalisation for vertebral fracture","volume":"15","author":"Kanis","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0135","first-page":"260","article-title":"Determinants of reduced survival following hip fractures in men","volume":"319","author":"Poor","year":"1995","journal-title":"Clin Orthop"},{"key":"10.1016\/j.bone.2013.11.002_bb0140","series-title":"Excess mortality after vertebral fracture","author":"Kanis","year":"2002"},{"key":"10.1016\/j.bone.2013.11.002_bb0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0033-3506(05)80614-6","article-title":"What is the true mortality of hip fractures?","volume":"105","author":"Parker","year":"1991","journal-title":"Public Health"},{"key":"10.1016\/j.bone.2013.11.002_bb0150","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","article-title":"The components of excess mortality after hip fracture","volume":"32","author":"Kanis","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.11.002_bb0155","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","article-title":"Meta-analysis: excess mortality after hip fracture among older women and men","volume":"152","author":"Haentjens","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bone.2013.11.002_bb0160","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.healthpol.2005.06.011","article-title":"A comparison of individual and social time trade-off values for health states in the general population","volume":"76","author":"Burstrom","year":"2006","journal-title":"Health Policy"},{"key":"10.1016\/j.bone.2013.11.002_bb0165","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00198-009-0844-y","article-title":"An updated systematic review of Health State Utility Values for osteoporosis related conditions","volume":"20","author":"Peasgood","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0170","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00198-003-1463-7","article-title":"The risk and burden of vertebral fractures in Sweden","volume":"15","author":"Kanis","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0175","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00198-006-0193-z","article-title":"An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials","volume":"17","author":"Borgstrom","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0180","first-page":"S184","article-title":"What is the risk of institutionalization after hip fracture?","volume":"17","author":"Zethraeus","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0185","series-title":"Systematic reviews of clinical effectiveness prepared for the guideline osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk","author":"National Institute for Health and Clinical Excellence (UK)","year":"2008"},{"key":"10.1016\/j.bone.2013.11.002_bb0190","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"NEJM"},{"key":"10.1016\/j.bone.2013.11.002_bb0195","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"NEJM"},{"key":"10.1016\/j.bone.2013.11.002_bb0200","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00198-007-0349-5","article-title":"Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries \u2014 an economic evaluation based on the fracture intervention trial","volume":"18","author":"Strom","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0205","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00019053-200422170-00005","article-title":"Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study","volume":"22","author":"Borgstrom","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.bone.2013.11.002_bb0210","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jama.298.6.629","article-title":"Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men","volume":"298","author":"Schousboe","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2013.11.002_bb0215","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","article-title":"Assessment of compliance with osteoporosis treatment and its consequences in a managed care population","volume":"38","author":"Huybrechts","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.11.002_bb0220","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","article-title":"Compliance with osteoporosis medications","volume":"165","author":"Solomon","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bone.2013.11.002_bb0225","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2013.11.002_bb0230","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","article-title":"Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment","volume":"20","author":"Prince","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.11.002_bb0235","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2007.10.019","article-title":"The cost-effectiveness of alendronate in the management of osteoporosis","volume":"42","author":"Kanis","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.11.002_bb0240","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/archinte.166.11.1209","article-title":"The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis","volume":"166","author":"Liu","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bone.2013.11.002_bb0245","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00198-011-1796-6","article-title":"A reappraisal of generic bisphosphonates in osteoporosis","volume":"23","author":"Kanis","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.11.002_bb0250","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"NEJM"},{"key":"10.1016\/j.bone.2013.11.002_bb0255","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","article-title":"Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk","volume":"96","author":"Boonen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2013.11.002_bb0260","article-title":"Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis","author":"McClung","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.11.002_bb0265","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.bone.2008.12.003","article-title":"Efficacy and safety of pharmacological agents in managing osteoporosis in the old: review of the evidence","volume":"44","author":"Inderjeeth","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.11.002_bb0270","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1532-5415.2009.02673.x","article-title":"Efficacy and safety of a once-yearly intravenous zoledronic acid 5mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older","volume":"58","author":"Boonen","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.bone.2013.11.002_bb0275","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1359\/jbmr.060404","article-title":"Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older","volume":"21","author":"Seeman","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.11.002_bb0280","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213004389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213004389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T18:22:50Z","timestamp":1539195770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328213004389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":54,"alternative-id":["S8756328213004389"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2013.11.002","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2013.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}